EU Explains Steps Sponsors Must Take When Using Companion Diagnostics In Drug Development
Executive Summary
A new Q&A document from the European Medicines Agency outlines the key steps that pharma companies should take when using companion diagnostics in clinical trials, and the information it expects to see in marketing authorization applications.